{"id":1179,"count":1,"description":"<p>Mirabegron, a\u015f\u0131r\u0131 aktif mesane belirtilerinde kullan\u0131labilen bir beta-3 adrenerjik resept\u00f6r agonistidir. Mesane kas\u0131n\u0131n gev\u015femesini sa\u011flayarak daha fazla idrar depolanmas\u0131na yard\u0131mc\u0131 olur. S\u0131k veya ani idrara \u00e7\u0131kma ihtiyac\u0131 ve s\u0131k\u0131\u015fmaya ba\u011fl\u0131 ka\u00e7\u0131rma gibi belirtiler \u00fczerinde etkili olabilir.<\/p><h2>\u0130drar yolu enfeksiyonu ilac\u0131 m\u0131?<\/h2><p>Mirabegron antibiyotik de\u011fildir. \u0130drarda yanma, ate\u015f veya yeni ba\u015flayan yak\u0131nmalar\u0131n b\u00fct\u00fcn nedenlerini tedavi etti\u011fi varsay\u0131lmamal\u0131d\u0131r. Mesane belirtilerinin kayna\u011f\u0131 \u00f6nce de\u011ferlendirilir. Etkinin tam fark edilmesi zaman alabilir; ilk kullan\u0131mla yeterli yarar g\u00f6r\u00fclmemesi ki\u015fisel doz de\u011fi\u015fikli\u011fi yapmak i\u00e7in gerek\u00e7e de\u011fildir. Kontroll\u00fc veya uzat\u0131lm\u0131\u015f sal\u0131ml\u0131 tabletin yap\u0131s\u0131, kullan\u0131m talimatlar\u0131n\u0131n \u00f6nemli bir par\u00e7as\u0131d\u0131r.<\/p><h2>Tansiyon ve di\u011fer g\u00fcvenlik konular\u0131<\/h2><p>Mirabegron tansiyonu y\u00fckseltebilir. Tedavi \u00f6ncesinde ve s\u0131ras\u0131nda kan bas\u0131nc\u0131n\u0131n kontrol edilmesi \u00f6nemlidir; a\u011f\u0131r ve kontrols\u00fcz hipertansiyonda kullan\u0131lmamas\u0131 gerekti\u011fi d\u00fczenleyici g\u00fcvenlik belgelerinde belirtilir. H\u0131zl\u0131 kalp at\u0131m\u0131 veya idrar yolu enfeksiyonu gibi etkiler g\u00f6r\u00fclebilir. B\u00f6brek veya karaci\u011fer hastal\u0131\u011f\u0131 ve birlikte kullan\u0131lan ila\u00e7lar ki\u015fiye uygunlu\u011fu etkiler. S\u0131k idrara \u00e7\u0131kman\u0131n azalmas\u0131, altta yatan b\u00fct\u00fcn mesane sorunlar\u0131n\u0131n ortadan kalkt\u0131\u011f\u0131n\u0131 g\u00f6stermez. A\u015fa\u011f\u0131daki kay\u0131tlar, mirabegron i\u00e7eren \u00fcr\u00fcnleri gruplar; ayn\u0131 yak\u0131nmas\u0131 olan herkesin bu maddeyi kullanabilece\u011fi anlam\u0131na gelmez. \u00dcr\u00fcne \u00f6zg\u00fc tablet b\u00fct\u00fcnl\u00fc\u011f\u00fc, doz ve takip kurallar\u0131 i\u00e7in doktor veya eczac\u0131 de\u011ferlendirmesi gerekir.<\/p><h2>Kaynaklar ve kapsam<\/h2><ul><li><a href=\"https:\/\/www.nhs.uk\/medicines\/mirabegron\/common-questions-about-mirabegron\/\" target=\"_blank\" rel=\"noopener\">NHS: Mirabegron s\u0131k sorulan sorular<\/a> (Birle\u015fik Krall\u0131k) \u2014 Beta-3 mekanizmas\u0131 ve etki beklentisi.<\/li><li><a href=\"https:\/\/www.gov.uk\/drug-safety-update\/mirabegron-betmiga-risk-of-severe-hypertension-and-associated-cerebrovascular-and-cardiac-events\" target=\"_blank\" rel=\"noopener\">MHRA: Mirabegron ve ciddi hipertansiyon<\/a> (Birle\u015fik Krall\u0131k) \u2014 Tansiyon kontrol\u00fc ve g\u00fcvenlik s\u0131n\u0131rlamalar\u0131.<\/li><li><a href=\"https:\/\/www.nhs.uk\/medicines\/mirabegron\/about-mirabegron\/\" target=\"_blank\" rel=\"noopener\">NHS: Mirabegron hakk\u0131nda<\/a> (Birle\u015fik Krall\u0131k) \u2014 Genel kullan\u0131m ve yan etki bilgisi.<\/li><\/ul><p><small>Kaynak kontrol\u00fc: <time datetime=\"2026-10-11\">11 Ekim 2026<\/time>. Kaynak do\u011frulamas\u0131 klinik uzman incelemesi de\u011fildir. \u0130\u00e7erik, kaynaklara dayal\u0131 yapay zek\u00e2 destekli genel bilgi \u00f6zetidir.<\/small><\/p>","link":"https:\/\/www.ortaakarsu.net\/?ism_etken_madde=mirabegron","name":"Mirabegron","slug":"mirabegron","taxonomy":"ism_etken_madde","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_etken_madde\/1179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/ism_etken_madde"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/taxonomies\/ism_etken_madde"}],"wp:post_type":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fism_drug&ism_etken_madde=1179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}